Enanta Pharmaceuticals, Inc. (ENTA) Cash Flow Statement
Enanta Pharmaceuticals, Inc. (ENTA) generated -$35.3M of operating cash flow over the twelve months to 2026-06-30, spent $1.6M on capital expenditure and had free cash flow of -$36.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ENTAEnanta Pharmaceuticals, Inc.Follow ENTA — free
—
Price chart with a free account
- Market cap
- 339.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
| Line | FY2013 Sep 13 | FY2014 Sep 14 | FY2015 Sep 15 | FY2016 Sep 16 | FY2017 Sep 17 | FY2018 Sep 18 | FY2019 Sep 19 | FY2020 Sep 20 | FY2021 Sep 21 | FY2022 Sep 22 | FY2023 Sep 23 | FY2024 Sep 24 | FY2025 Sep 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 10.7 | 20.2 | 76.7 | 35.8 | 52.7 | 29.2 | 71.4 | 7.1 | -70.0 | -84.8 | -103.2 | -78.8 | -19.3 | -35.3 | |
| Capital expenditure | 0.6 | 1.0 | 2.3 | 4.7 | 2.5 | 3.0 | 5.4 | 1.4 | 0.8 | 2.1 | 9.1 | 17.9 | 12.9 | -1.6 | |
| Free cash flow | 10.0 | 19.2 | 74.3 | 31.1 | 50.1 | 26.2 | 66.0 | 5.6 | -70.7 | -86.9 | -112.2 | -96.7 | -32.2 | -36.9 | |
| Stock-based compensation | 1.1 | 2.7 | 5.8 | 9.4 | 13.1 | 15.8 | 19.2 | 19.6 | 21.0 | 27.0 | 28.2 | 26.8 | 18.6 | — |
USD millions · SEC XBRL
Enanta Pharmaceuticals, Inc. — questions
- What is Enanta Pharmaceuticals, Inc.'s operating cash flow?
- -$35.3M over the twelve months to 2026-06-30.
- How much does Enanta Pharmaceuticals, Inc. spend on capital expenditure?
- $1.6M over the twelve months to 2026-06-30.
- What is Enanta Pharmaceuticals, Inc.'s free cash flow?
- -$36.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Enanta Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.